The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Leland Gershell - Oppenheimer & Co. Inc. - Analyst
: Lonnel, thank you very much for that terrific overview and going through the programs. A few questions here. For those of us who are less up to
speed on the SGLT space, if you could maybe discuss, is there any other information to learn about empagliflozin that would be like another shoe
to fall in terms of data. And whether it's HFrEF or HFpEF that could change how we think about sotagliflozin's opportunity in these indications.
And I think you'd also mentioned there was a third player in this mechanism. Just wanted to ask about the -- kind of what the competitive potential
of that is. Thank you.
Question: Leland Gershell - Oppenheimer & Co. Inc. - Analyst
: And then you confirmed, you said the guidelines are under revision and we could see it, kind of the final announcement sometime next year?
Question: Leland Gershell - Oppenheimer & Co. Inc. - Analyst
: And you've done a fair bit of work looking at yourselves as a commercial player in the space and taking this to market. How should we think about
kind of the sales force size and deployment? And you're going up against some bigger companies there, so just wanted to maybe dig a little bit
further in terms of how you see kind of the sales and marketing line in your P&L playing out as we think about Lexicon going commercial with sota?
Question: Leland Gershell - Oppenheimer & Co. Inc. - Analyst
: Got you. No, that's very helpful. And a question or two in the neuropathic pain program. So I just wanted to ask in the RELIEF studies, I believe the
DPN study is several times larger than PHN. Just wanted to ask what the driver of that size difference of those trials.
Question: Leland Gershell - Oppenheimer & Co. Inc. - Analyst
: And obviously pain has always been a big market and we are always welcoming new therapies that are not opioids and like those kinds of liabilities.
Are there others that have looked at this particular mechanism and target that provide an extra validation or is Lexicon kind of the pioneer for that?
Question: Leland Gershell - Oppenheimer & Co. Inc. - Analyst
: Terrific. Well, I think we are right up at our time here. So with that, Lonnel and Chas and Jeff, thanks for joining us and look forward to following
the progress. And thanks to everyone for participating. Have a great day.
| 
